First task order for the purchase of octaplaslg for program executive office - operational medicine.
Ended Awarded
- Contract number
- HT942525FE059
- Awardee
-
Octapharma USA Inc. UEI FKJKNJVR1HV4
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $2,000,000
Award facts
- Contract value 100% obligated
- $2,000,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- Funding agency
- Joint PEO Chemical and Biological Defense Acquisition Support Center, Department of Defense
- NAICS code
- 325414 Biological Product (except Diagnostic) Manufacturing
- Set-aside
- No set-aside
- Competition
- Not Available for Competition Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- Travis AFB, Fairfield, CA, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
Award details come from SAM.gov/FPDS.
About this award
The U.S. Defense Department's Joint Program Executive Office for Chemical and Biological Defense awarded a $2 million firm fixed-price delivery order to Octapharma USA Inc. (UEI: FKJKNJVR1HV4) on September 16, 2025, for the purchase of Octaplas LG in support of the Program Executive Office for Operational Medicine. Octaplas LG is a liquid plasma product used for hemorrhage control and coagulation support in emergency medical situations. The contract carries no set-aside designation and will be performed at Travis Air Force Base in Fairfield, California, with an ultimate completion date of January 16, 2026.
This delivery order represents the first task order issued under what is likely a broader medical supply contract vehicle supporting the Defense Department's operational medicine capabilities. The Program Executive Office for Operational Medicine manages medical readiness and treatment capabilities across the military, and this procurement ensures adequate supply of critical blood products for military medical facilities and field operations. The relatively near-term completion date and single-vendor award indicate an urgent requirement for this specialized pharmaceutical product to support military medical readiness.
Quick answers
Who was awarded contract HT942525FE059?
HT942525FE059 was awarded to Octapharma USA Inc. by Defense Health Agency (Department of Defense) on September 16, 2025.
How much is contract HT942525FE059 worth?
The government has obligated $2,000,000 on HT942525FE059.
Which agency awarded contract HT942525FE059?
Defense Health Agency (Department of Defense) awarded HT942525FE059, with funding from Joint PEO Chemical and Biological Defense (Acquisition Support Center).
Is contract HT942525FE059 an order under another contract?
Yes. HT942525FE059 is a delivery order under HT942525DE004, an indefinite delivery contract.
Was contract HT942525FE059 competed?
The extent of competition for HT942525FE059 was not available for competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award